Buprenorphine | Pharmacology Mentor

Generic Name

Buprenorphine

Mechanism

Partial agonism at μ‑opioid receptor (MOR)
Provides analgesia and euphoric effects, but with a ceiling effect for respiratory depression and sedation.
High‑affinity antagonist at κ‑opioid receptor (KOR)
Reduces dysphoria and psychotomimetic side effects commonly seen with full MOR agonists.
Immobility at the δ‑opioid receptor
Minimizes potential for tolerance development relative to full agonists.
Partial agonist activity also blocks opioid receptor up‑regulation
Useful in treating OUD by attenuating withdrawal and craving while discouraging abuse potential.

---

Pharmacokinetics

Parameter	Detail
Absorption	Sublingual: rapid oral bioavailability (~30–50%); Transdermal patch: steady‑state delivery over 7 days; Intravenous: 100% bioavailability.
Distribution	Highly lipophilic; 99% protein‑bound primarily to albumin & α‑1‑acid glycoprotein; large volume of distribution (~2–8 L/kg).
Metabolism	Extensive hepatic metabolism (CYP3A4 → oxidized metabolites; UGT1A3, UGT2B7 → glucuronides).
Elimination	Renal excretion of metabolites (≈70%); terminal half‑life ~ 27–72 h (longer in patches and chronic dosing).
Drug Interactions	Potentiating: strong CYP3A4/1A2 inhibitors (ketoconazole, clarithromycin, HIV protease inhibitors). Lowering: CYP3A4 inducers (rifampin, carbamazepine).
Special Populations	Cirrhosis: ↓ clearance → increased exposure. Renal impairment: negligible impact due to hepatic metabolism. Pregnancy: category C; limited data; use only if benefits outweigh risks.

--
•

Indications

Chronic, non‑cancer pain (intermittent or continuous) – sublingual, buccal, or extended‑release oral formulations.
Acute pain – sublingual or IV formulations in opioid‑naïve or tolerant patients.
Opioid Use Disorder (OUD) – sublingual tablet/film or buprenorphine/naloxone combo (“Suboxone”) to reduce withdrawal and cravings.
Transdermal patch – moderate to severe chronic pain when oral administration is problematic.

---

Contraindications

Condition	Reason	Note
Pregnancy & lactation	Lack of robust safety data; avoid unless benefits outweigh potential fetal risk.
Hypersensitivity to Buprenorphine	Cross‑reactivity with other opioids.
Severe respiratory depression, acute opioid overdose	Buprenorphine’s ceiling effect can mask respiratory risk; avoid in overdosing patients with severe hypoventilation.
Co‑administration with potent central nervous system (CNS) depressants	Risk of additive sedation, apnea.
Uncorrected electrolyte instability (hypokalemia, hypomagnesemia)	Can precipitate QTc prolongation on certain patch formulations.

Warnings
• Ceiling effect only applies to respiratory depression; vigilance required in new users or drug‑interaction settings.
• Risk of relapse in OUD if tapering is abrupt; requires structured counseling and gradual dose reduction.
• Potential for misuse if not monitored; Suboxone’s naloxone component mitigates intravenous abuse.

--
•

Dosing

Indication	Formulation	Starting Dose	Titration	Maintenance Dose	Tapering Tips
Acute pain (IV or sublingual)	IV 0.2–0.3 mg q6h (max 3 mg/day)	N/A	Up to 0.3 mg q6h	0.6–2 mg q8h	Taper 0.2 mg/3–4 days
Chronic pain (sublingual)	Sublingual 0.2 mg twice daily	0.2 mg BID	Add 0.2 mg BID every 4–7 days	0.4–2 mg BID	Extend interval 3–5 days per 20–30 % dose reduction
Chronic pain (transdermal patch)	5 µg/h patch (28 days)	5 µg/h	Increase every 28 days if inadequate	10–25 µg/h	Gradual dose reduction 5 µg/h every 28 days
OUD (Suboxone)	8/2 mg film, 2–4 drops	2 mg (Buprenorphine)	Add 2 mg every 2–3 days until 12–16 mg/day	12–16 mg daily (titrated)	Taper 2 mg per week for 12–16 weeks, with close monitoring

Admin Notes
• Sublingual: dissolve under tongue, avoid swallowing for 30 min.
• Transdermal: apply fresh patch to intact skin; rotate sites to avoid irritation.
• Intravenous: flush with saline; administer slowly (≤1 mg/min).

--
•

Adverse Effects

Common (≥10 %)
• Nausea, vomiting
• Constipation
• Somnolence, dizziness
• Headache
• Irritability
• Injection site pain (IV or patch)

Serious (≤1 %)
• Respiratory depression (especially with other CNS depressants)
• Hypotension (rare)
• Severe allergic reactions (anaphylaxis)
• QTc prolongation (rare, patch users)
• Hepatic injury (esp. with concomitant hepatotoxic drugs)

---

Monitoring

Parameter	Frequency	Rationale
Respiratory rate & oxygen saturation	Every 4–8 h during initiation or dose changes; daily thereafter.	Detect respiratory depression early.
Pain scores (VAS/NRS)	Baseline and every 6–12 h during the first 24 h of IV or sublingual therapy; weekly for chronic dosing.	Optimize analgesia while minimizing over‑dose.
Constitutional signs (flu-like symptoms, sweating)	During dose escalation or taper.	Identify early withdrawal or adverse effects.
Liver function tests (AST/ALT)	Baseline; repeat at 4–6 weeks in chronic users, especially those on CYP3A4 inhibitors.	Monitor for hepatotoxicity.
Serum electrolyte panel	Baseline & every 2–4 weeks in patients on patches (especially if on QT prolonging drugs).	Guard against arrhythmia.
Blood pressure & heart rate	Baseline; monitor after each dose escalation.	Detect hypotension.
Urine drug screen	As part of OUD management every 2–4 weeks.	Ensure compliance & detect diversion.
Adverse event reporting	At every encounter.	Contribute to pharmacovigilance.

--
•

Clinical Pearls

Ceiling vs. Tolerability: The ceiling effect protects against respiratory depression but does not limit analgesic efficacy; titration should still consider pain relief over safety.
Sublingual vs. IV: Sublingual has ~30–50% bioavailability; IV gives full effect but is limited to hospital settings or IV‑naïve patients; the transition from IV to sublingual should be gradual (≤2 mg/day).
Combining with Naloxone (Suboxone): Naloxone is poorly absorbed orally, so it only deters IV abuse while maintaining sublingual efficacy. Essential for OUD patients with a history of injection.
Patch-specific: Use the 2‑week “wash‑in” period for chronic pain patients before initiating or increasing doses.
Hepatic impairment: In Child‑Pugh class A, no dose adjustment; in class B–C, consider lower starting dose and slower titration.
Drug‑Drug Interactions: Strong CYP3A4 inhibitors can raise buprenorphine plasma levels by >3×—doses often halved; strong inducers may reduce efficacy by >50%.
Rapid Tapering: Abrupt dose reduction within 72 h can precipitate withdrawal; a 1–2 mg/day decrease per week is safest.
Pregnancy & Lactation: While data are limited, cross‑placental transfer occurs; avoid if not absolutely necessary. Breastfeeding is not recommended.
Monitoring Respiratory Depression: Even patients on a stable dose can experience depression if combined with benzodiazepines, alcohol, or other CNS depressants.

Key Takeaway

Buprenorphine’s partial agonist profile, long half‑life, and safety ceiling make it an indispensable tool for both pain control and OUD, but careful dosing, monitoring, and patient education are critical to maximize benefit and minimize risk.